Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
The Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, M5G 1X5, Canada; Division of Clinical and Metabolic Genetics, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, M5G 1X8, Canada.
Am J Hum Genet. 2020 Jan 2;106(1):121-128. doi: 10.1016/j.ajhg.2019.12.004. Epub 2019 Dec 26.
In two independent ongoing next-generation sequencing projects for individuals with holoprosencephaly and individuals with disorders of sex development, and through international research collaboration, we identified twelve individuals with de novo loss-of-function (LoF) variants in protein phosphatase 1, regulatory subunit 12a (PPP1R12A), an important developmental gene involved in cell migration, adhesion, and morphogenesis. This gene has not been previously reported in association with human disease, and it has intolerance to LoF as illustrated by a very low observed-to-expected ratio of LoF variants in gnomAD. Of the twelve individuals, midline brain malformations were found in five, urogenital anomalies in nine, and a combination of both phenotypes in two. Other congenital anomalies identified included omphalocele, jejunal, and ileal atresia with aberrant mesenteric blood supply, and syndactyly. Six individuals had stop gain variants, five had a deletion or duplication resulting in a frameshift, and one had a canonical splice acceptor site loss. Murine and human in situ hybridization and immunostaining revealed PPP1R12A expression in the prosencephalic neural folds and protein localization in the lower urinary tract at critical periods for forebrain division and urogenital development. Based on these clinical and molecular findings, we propose the association of PPP1R12A pathogenic variants with a congenital malformations syndrome affecting the embryogenesis of the brain and genitourinary systems and including disorders of sex development.
在两个独立的、针对无脑畸形患者和性发育障碍患者的新一代测序项目中,以及通过国际研究合作,我们鉴定出 12 名个体存在 PPP1R12A 蛋白磷酸酶 1 调节亚基 12a(PPP1R12A)的新生功能丧失(LoF)变异,该基因是参与细胞迁移、黏附和形态发生的重要发育基因。该基因以前未与人类疾病相关联,并且具有 LoF 不耐受性,因为在 gnomAD 中观察到的 LoF 变异的观察到的预期比值非常低。在这 12 名个体中,5 名存在中线脑畸形,9 名存在泌尿生殖系统异常,2 名存在两种表型的组合。鉴定出的其他先天性异常包括脐膨出、空肠和回肠闭锁伴异常肠系膜血液供应以及并指畸形。6 名个体存在终止获得变异,5 名个体存在导致移码的缺失或重复,1 名个体存在经典剪接受体位点缺失。鼠和人原位杂交和免疫染色显示 PPP1R12A 在前脑分裂和泌尿生殖系统发育的关键时期在 prosencephalic 神经褶中表达,并在蛋白质定位在下泌尿道中。基于这些临床和分子发现,我们提出 PPP1R12A 致病变异与影响脑和生殖泌尿系统胚胎发生的先天性畸形综合征相关联,包括性发育障碍。